PL2179732T3 - Kompozycja farmaceutyczna łącząca środek hamujący enzym reduktazę HMG-CoA i środek hamujący enzymy lipazy żołądkowo-jelitowe - Google Patents
Kompozycja farmaceutyczna łącząca środek hamujący enzym reduktazę HMG-CoA i środek hamujący enzymy lipazy żołądkowo-jelitoweInfo
- Publication number
- PL2179732T3 PL2179732T3 PL08778967T PL08778967T PL2179732T3 PL 2179732 T3 PL2179732 T3 PL 2179732T3 PL 08778967 T PL08778967 T PL 08778967T PL 08778967 T PL08778967 T PL 08778967T PL 2179732 T3 PL2179732 T3 PL 2179732T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibiting agent
- enzyme
- pharmaceutical composition
- coa reductase
- composition combining
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title 2
- 230000002401 inhibitory effect Effects 0.000 title 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title 1
- 102000004882 Lipase Human genes 0.000 title 1
- 108090001060 Lipase Proteins 0.000 title 1
- 230000002496 gastric effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007007283A MX2007007283A (es) | 2007-06-15 | 2007-06-15 | Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal. |
| PCT/MX2008/000077 WO2008153374A1 (es) | 2007-06-15 | 2008-06-16 | Composición farmacéutica que comprende la combinación de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal |
| EP08778967.3A EP2179732B1 (en) | 2007-06-15 | 2008-06-16 | Pharmaceutical composition combining an enzyme hmg-coa reductase inhibiting agent and a gastrointestinal lipase enzyme inhibiting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2179732T3 true PL2179732T3 (pl) | 2014-10-31 |
Family
ID=40129898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08778967T PL2179732T3 (pl) | 2007-06-15 | 2008-06-16 | Kompozycja farmaceutyczna łącząca środek hamujący enzym reduktazę HMG-CoA i środek hamujący enzymy lipazy żołądkowo-jelitowe |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2179732B1 (pl) |
| AR (1) | AR067038A1 (pl) |
| BR (1) | BRPI0813174A2 (pl) |
| CO (1) | CO6241106A2 (pl) |
| CY (1) | CY1115453T1 (pl) |
| EC (1) | ECSP099801A (pl) |
| ES (1) | ES2492665T3 (pl) |
| GT (1) | GT200900316A (pl) |
| MX (1) | MX2007007283A (pl) |
| PL (1) | PL2179732T3 (pl) |
| UY (1) | UY31211A1 (pl) |
| WO (1) | WO2008153374A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110314232A (zh) * | 2019-08-03 | 2019-10-11 | 黄泳华 | 由脂肪酶抑制剂与羟甲戊二酰辅酶a还原酶抑制剂构成的组合物 |
| AR133035A1 (es) * | 2023-06-21 | 2025-08-20 | Shanghai Argo Biopharmaceutical Co Ltd | Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005000217A2 (en) * | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
| WO2006109170A2 (en) * | 2005-04-14 | 2006-10-19 | Esperion Therapeutics Inc. | Combination therapy for treatment of cardiovascular diseases and related conditions |
| MXPA06010973A (es) * | 2006-09-25 | 2009-02-18 | World Trade Imp Export Wtie Ag | Composicion farmaceutica para el tratamiento del sobrepeso y la obesidad que se acompañan la dislipidemia. |
-
2007
- 2007-06-15 MX MX2007007283A patent/MX2007007283A/es active IP Right Grant
-
2008
- 2008-06-16 ES ES08778967.3T patent/ES2492665T3/es active Active
- 2008-06-16 PL PL08778967T patent/PL2179732T3/pl unknown
- 2008-06-16 EP EP08778967.3A patent/EP2179732B1/en not_active Not-in-force
- 2008-06-16 WO PCT/MX2008/000077 patent/WO2008153374A1/es not_active Ceased
- 2008-06-16 BR BRPI0813174-0A2A patent/BRPI0813174A2/pt not_active Application Discontinuation
- 2008-06-17 AR ARP080102585A patent/AR067038A1/es unknown
- 2008-07-04 UY UY31211A patent/UY31211A1/es not_active Application Discontinuation
-
2009
- 2009-12-11 CO CO09141944A patent/CO6241106A2/es not_active Application Discontinuation
- 2009-12-14 EC EC2009009801A patent/ECSP099801A/es unknown
- 2009-12-14 GT GT200900316A patent/GT200900316A/es unknown
-
2014
- 2014-08-07 CY CY20141100617T patent/CY1115453T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT200900316A (es) | 2011-07-25 |
| ECSP099801A (es) | 2010-01-29 |
| MX2007007283A (es) | 2009-02-18 |
| BRPI0813174A2 (pt) | 2014-12-23 |
| UY31211A1 (es) | 2009-01-05 |
| EP2179732A4 (en) | 2010-08-25 |
| AR067038A1 (es) | 2009-09-30 |
| ES2492665T3 (es) | 2014-09-10 |
| EP2179732A1 (en) | 2010-04-28 |
| WO2008153374A1 (es) | 2008-12-18 |
| WO2008153374A8 (es) | 2010-02-04 |
| EP2179732B1 (en) | 2014-05-14 |
| CY1115453T1 (el) | 2017-01-04 |
| CO6241106A2 (es) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL198349A0 (en) | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors | |
| GB0619753D0 (en) | Enzyme inhibitors | |
| ZA200903598B (en) | Lipase variants for pharmaceutical use | |
| IL197091A0 (en) | Soluble epoxide hydrolase inhibitors | |
| IL190715A0 (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| EP2056835A4 (en) | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| IL197190A0 (en) | Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors | |
| IL194339A0 (en) | Enzyme inhibitors | |
| ZA200802370B (en) | Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases | |
| EP2180891A4 (en) | COMBINATION PREPARATION WITH HMG COA REDUCTASE INHIBITORS AND ASPIRIN AND METHOD FOR THE PRODUCTION THEREOF | |
| IL196251A0 (en) | Soluble epoxide hydrolase inhibitors | |
| AU2007260950A8 (en) | Methods and compositions for targeting HEPSIN | |
| IL193469A0 (en) | Novel lipases and uses thereof | |
| IL187730A0 (en) | Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors | |
| IL187728A0 (en) | Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors | |
| EP2070919A4 (en) | SPIROCHINONE COMPOUND AND PHARMACEUTICAL COMPOSITION | |
| IL187729A0 (en) | Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors | |
| IL197233A0 (en) | Soluble epoxide hydrolase inhibitors | |
| EP2049102A4 (en) | POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE | |
| GB0608821D0 (en) | DHFR enzyme inhibitors | |
| EP2179732A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE ENZYME INHIBITING AGENT AND GATROINTESTINAL ENZYME LIPASE INHIBITOR AGENT | |
| EP1871396A4 (en) | STABILIZED PHARMACEUTICAL COMPOSITIONS WITH AN HMG COA REDUCTASE INHIBITOR | |
| IL193585A0 (en) | Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor | |
| EP2114404A4 (en) | COMPOUND AND PHARMACEUTICAL COMPOSITION | |
| GB0608844D0 (en) | Enzyme inhibitors |